News for XTL Biopharmaceuticals Ltd. (XTLB)

News for XTL Biopharmaceuticals Ltd.
Date Headline
Jul 16, 2014 09:18 AM XTL Bio's hCDR1 Compound Highlighted in Article Reviewing Potential Candidates for the Treatment of Lupus Published in Journal of Autoimmunity
Jun 12, 2014 08:00 AM XTL Biopharmaceuticals Receives Correspondence Regarding Nasdaq Listing Requirements
Jun 02, 2014 09:00 AM XTL Biopharmaceuticals Reports Financial and Operational Results for the First Quarter of 2014
May 19, 2014 08:00 AM XTL Biopharmaceuticals Further Strengthens Team for Phase II Lupus Trial with Two Additional Experts
Apr 10, 2014 01:04 PM XTL BIOPHARMACEUTICALS LTD Financials
Apr 02, 2014 04:41 PM XTL Biopharmaceuticals Reports Financial and Operational Results for the Full Year Ended 2013
Mar 25, 2014 08:00 AM XTL Biopharmaceuticals Retains Expert Consultants in Rheumatology for Phase II Lupus Trial
Jan 08, 2014 08:00 AM XTL Biopharmaceuticals In-licenses hCDR1, a Phase 2 Clinical Stage Asset for the Treatment of Lupus
Jul 15, 2013 01:30 PM XTL Biopharmaceuticals' ADRs Commence Trading on NASDAQ Stock Market